Enliven therapeutics appoints dr. lori kunkel to board of directors

Boulder, colo., april 09, 2024 (globe newswire) -- enliven therapeutics, inc. (enliven or the company) (nasdaq: elvn), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of lori kunkel, md, to its board of directors. dr. kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the board.
ELVN Ratings Summary
ELVN Quant Ranking